[go: up one dir, main page]

MX2020001432A - Anticuerpos que se unen al receptor del factor de crecimiento epidermico (egfr) y tirosina-proteina cinasa met (cmet). - Google Patents

Anticuerpos que se unen al receptor del factor de crecimiento epidermico (egfr) y tirosina-proteina cinasa met (cmet).

Info

Publication number
MX2020001432A
MX2020001432A MX2020001432A MX2020001432A MX2020001432A MX 2020001432 A MX2020001432 A MX 2020001432A MX 2020001432 A MX2020001432 A MX 2020001432A MX 2020001432 A MX2020001432 A MX 2020001432A MX 2020001432 A MX2020001432 A MX 2020001432A
Authority
MX
Mexico
Prior art keywords
antibody
bind
variable domain
cmet
egfr
Prior art date
Application number
MX2020001432A
Other languages
English (en)
Inventor
Throsby Mark
Anna Wilhelmina Geuijen Cecilia
Adriaan De Kruif Cornelis
Logtenberg Ton
Cornelis Roovers Robertus
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MX2020001432A publication Critical patent/MX2020001432A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a anticuerpos biespecíficos que comprenden un primer dominio variable que puede unirse a una parte extracelular del receptor del factor de crecimiento epidérmico (EGFR) y un segundo dominio variable que puede unirse a una parte extracelular del Proto-Oncogén de MET, Receptor de Tirosina Cinasa (cMET). El anticuerpo puede comprender una cadena ligera común. Puede ser un anticuerpo humano. El anticuerpo puede ser un anticuerpo de longitud completa. En algunas modalidades el anticuerpo biespecífico es un anticuerpo de formato IgG1 que tiene una estequiometria anti-cMET, anti-EGFR de 1:1. En algunas modalidades, el anticuerpo tiene un dominio variable que puede unirse al EGFR y un dominio variable que puede unirse a cMET.
MX2020001432A 2017-08-09 2018-08-09 Anticuerpos que se unen al receptor del factor de crecimiento epidermico (egfr) y tirosina-proteina cinasa met (cmet). MX2020001432A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17185572 2017-08-09
PCT/NL2018/050537 WO2019031965A1 (en) 2017-08-09 2018-08-09 ANTIBODIES THAT BIND EGFR AND CMET

Publications (1)

Publication Number Publication Date
MX2020001432A true MX2020001432A (es) 2020-03-20

Family

ID=59579503

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001432A MX2020001432A (es) 2017-08-09 2018-08-09 Anticuerpos que se unen al receptor del factor de crecimiento epidermico (egfr) y tirosina-proteina cinasa met (cmet).

Country Status (25)

Country Link
US (2) US11773170B2 (es)
EP (2) EP4553088A2 (es)
JP (2) JP2020530028A (es)
KR (1) KR20200042485A (es)
CN (4) CN118580366A (es)
AU (2) AU2018312816B2 (es)
BR (1) BR112020002695A2 (es)
CA (1) CA3072404A1 (es)
DK (1) DK3665198T3 (es)
EA (1) EA202090215A1 (es)
ES (1) ES3025738T3 (es)
FI (1) FI3665198T3 (es)
HR (1) HRP20250474T1 (es)
IL (1) IL272461A (es)
LT (1) LT3665198T (es)
MA (2) MA71419A (es)
MX (1) MX2020001432A (es)
PH (1) PH12020550055A1 (es)
PL (1) PL3665198T3 (es)
PT (1) PT3665198T (es)
RS (1) RS66708B1 (es)
SG (1) SG11202001050PA (es)
SI (1) SI3665198T1 (es)
TW (1) TWI874301B (es)
WO (1) WO2019031965A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180100305A (ko) 2015-10-23 2018-09-10 메뤼스 엔.페. 암 성장을 억제하는 결합 분자
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
KR20200139189A (ko) * 2018-03-30 2020-12-11 메뤼스 엔.페. 다가 항체
JP2022520632A (ja) * 2019-02-15 2022-03-31 インテグラル・モレキュラー・インコーポレイテッド 共通軽鎖を含む抗体及びその使用
PH12021552833A1 (en) 2019-05-09 2023-01-16 Merus Nv Variant domains for multimerizing proteins and separation thereof
MX2022002886A (es) 2019-09-16 2022-04-06 Regeneron Pharma Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.
CN112898427B (zh) * 2019-12-03 2023-06-30 同济大学苏州研究院 一种抗c-Met单臂抗体及其制备方法和应用
KR20240032959A (ko) 2021-07-14 2024-03-12 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Hgfr 및 egfr에 특이적으로 결합하는 항원-결합 분자, 및 이의 약학적 용도
WO2023172133A1 (en) 2022-03-07 2023-09-14 Merus N.V. Combination therapy including antibodies that bind egfr and cmet
CN120058955A (zh) 2022-03-07 2025-05-30 美勒斯公司 用结合EGFR和cMET的抗体治疗
WO2024002235A1 (en) * 2022-06-29 2024-01-04 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-egfr/met antibodies and uses thereof
CN120035608A (zh) 2022-11-24 2025-05-23 江苏恒瑞医药股份有限公司 一种包含特异性结合hgfr和egfr的双特异性抗体的药物组合物
WO2025025434A1 (zh) * 2023-08-02 2025-02-06 百泰生物药业有限公司 EGFR/c-Met双特异性抗体及其应用
WO2025105961A1 (en) 2023-11-17 2025-05-22 Merus N.V. COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND cMET.

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
KR100255717B1 (ko) 1991-07-15 2000-05-01 그레이엄 브레레톤 항체의 생산방법
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE29706518U1 (de) 1997-04-11 1997-05-22 E. Missel GmbH & Co., 70374 Stuttgart Trägersystem für Bade-, Dusch- oder Whirlwannen
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK1161548T4 (da) 1999-04-15 2010-03-01 Crucell Holland Bv Rekombinant proteinproduktion i en human celle under anvendelse af sekvenser, der koder for adenovirus E1-protein
DE29915950U1 (de) 1999-09-10 1999-12-30 CMW Automation GmbH, 65594 Runkel Vorrichtung zum Elektrolytbefüllen der Zellen eines Akkumulators
US20070111201A1 (en) 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
ATE466941T1 (de) 2001-07-04 2010-05-15 Chromagenics Bv Dns-sequenzen mit anti-repressor-aktivität
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
WO2003107218A1 (ja) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 相互作用予測装置
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
JP4589914B2 (ja) 2003-01-07 2010-12-01 シムフォゲン・アクティーゼルスカブ 組換え型ポリクローナルタンパク質の製造方法
EP2322547A1 (en) 2003-06-25 2011-05-18 Crucell Holland B.V. Myeloid cell-specific lectin
KR101201464B1 (ko) 2004-05-05 2012-11-14 메리맥 파마슈티컬즈, 인크. 생물학적 활성을 조정하기 위한 이특이성 결합제
MXPA06014075A (es) 2004-06-03 2007-03-15 Novimmune Sa Anticuerpos anti-cd3 y metodos de uso de los mismos.
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006091209A2 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
EP2091975A4 (en) 2006-11-21 2013-05-22 Univ California ANTIBODIES TO THE EGFR FAMILY, BICE-SPECIFIC ANTIBODIES TO THE EGFR FAMILY AND METHOD FOR THEIR USE
CA2678181C (en) 2007-02-16 2016-12-13 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
CA2681974C (en) 2007-03-29 2019-12-31 Genmab A/S Bispecific antibodies and methods for production thereof
KR101626988B1 (ko) 2007-04-03 2016-06-02 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 이중특이적인 결합제들
US7705103B2 (en) 2007-06-22 2010-04-27 3M Innovative Properties Company Polydiorganosiloxane polyoxamide copolymers
AU2008270972B2 (en) 2007-07-02 2013-10-24 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
EP2211903A4 (en) 2007-10-17 2011-07-06 Nuvelo Inc CLL-1 ANTIBODY
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
US9404928B2 (en) 2008-02-05 2016-08-02 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
SI2147594T1 (sl) 2008-06-27 2014-02-28 Merus B.V. Protitelo proizvajajoči ne-humani sesalci
US8663640B2 (en) 2008-08-29 2014-03-04 Symphogen A/S Methods using recombinant anti-epidermal growth factor receptor antibody compositions
BRPI0921586A2 (pt) 2008-11-18 2019-09-24 Merrimack Pharmaceuticals Inc articuladores de albumina de soro humana e conjugados destes
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
KR20110120891A (ko) 2009-01-15 2011-11-04 래버러토리 코포레이션 오브 아메리카 홀딩스 Ｈｅｒ-３의 측정에 의한 환자 반응의 결정 방법
WO2010084197A1 (en) 2009-01-26 2010-07-29 Genmab A/S Methods for producing mixtures of antibodies
TWI461211B (zh) 2009-03-20 2014-11-21 Genentech Inc 抗－ｈｅｒ抗體
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MX342623B (es) 2009-06-26 2016-10-06 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
BR112012003809A2 (pt) 2009-08-21 2019-09-24 Merrimack Pharmaceuticals Inc anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo.
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP5960598B2 (ja) 2009-11-04 2016-08-02 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
RU2724663C2 (ru) 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CA2808482C (en) 2010-08-16 2021-10-26 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
WO2012022814A1 (en) 2010-08-20 2012-02-23 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
MX2013009732A (es) 2011-02-24 2013-12-06 Merrimack Pharmaceuticals Inc Terapias de combinacion comprendiendo agentes anti-erbb3.
EP2683741A2 (en) 2011-03-11 2014-01-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
CA2828043A1 (en) 2011-03-15 2012-09-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
KR20200052383A (ko) 2011-03-25 2020-05-14 아이크노스 사이언스 에스. 아. 헤테로 이량체 면역글로불린
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
NO2707391T3 (es) 2011-05-13 2018-04-07
EP2722343A4 (en) 2011-06-20 2014-12-17 Kyowa Hakko Kirin Co Ltd ANTI-ERBB3 ANTIBODIES
EP2731625B1 (en) 2011-07-15 2018-04-18 OncoMed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
US9567827B2 (en) 2013-07-15 2017-02-14 Downhole Technology, Llc Downhole tool and method of use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
CN103917562B (zh) 2011-09-30 2016-07-06 瑞泽恩制药公司 抗-ErbB3抗体及其用途
CN104093743B (zh) 2011-11-23 2018-04-24 医学免疫有限责任公司 特异于her3的结合分子及其用途
ES2758433T3 (es) 2011-12-05 2020-05-05 Novartis Ag Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
SG11201402784WA (en) 2011-12-05 2014-06-27 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
CN102448183A (zh) 2012-01-18 2012-05-09 大唐移动通信设备有限公司 一种Uu接口重配置方法及设备
WO2013134686A1 (en) 2012-03-09 2013-09-12 Promega Corporation pH SENSORS
SG11201406079TA (en) 2012-03-27 2014-10-30 Genentech Inc Diagnosis and treatments relating to her3 inhibitors
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
PL2838917T3 (pl) 2012-04-20 2019-12-31 Merus N.V. Sposoby i środki do wytwarzania heterodimerycznych cząsteczek podobnych do Ig
TW201843172A (zh) * 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
ES2692951T3 (es) 2012-09-27 2018-12-05 Merus N.V. Anticuerpos IgG biespecíficos como acopladores de células T
JP2015532306A (ja) 2012-10-15 2015-11-09 チューリッヒ大学 癌治療のための二重特異性ｈｅｒ２リガンド
ES2700231T3 (es) * 2012-11-21 2019-02-14 Janssen Biotech Inc Anticuerpos de EGFR/c-Met biespecíficos
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
CA2900955A1 (en) 2013-03-14 2014-10-02 Oncomed Pharmaceuticals, Inc. Met-binding agents and uses thereof
CA2908515A1 (en) 2013-04-05 2014-10-09 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
EP2994164B1 (en) 2013-05-08 2020-08-05 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
WO2014197854A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
WO2015018918A1 (en) 2013-08-07 2015-02-12 Universität Zu Köln Novel nrg1 fusion genes in cancer
US9551208B2 (en) 2013-08-26 2017-01-24 Halliburton Energy Services, Inc. Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation
WO2015066543A1 (en) 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
EP3786186A1 (en) * 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
KR20160145560A (ko) 2014-02-28 2016-12-20 메뤼스 엔.페. ErbB-2와 ErbB-3에 결합하는 항체
US9475875B2 (en) 2014-03-11 2016-10-25 Regeneron Pharmaceuticals, Inc. Anti-EGFRvIII antibodies and uses thereof
US9546214B2 (en) 2014-04-04 2017-01-17 Bionomics, Inc. Humanized antibodies that bind LGR5
US10813952B2 (en) 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
JP7010811B2 (ja) 2015-07-10 2022-02-10 メルス ナムローゼ フェンノートシャップ ヒトｃｄ３結合抗体
US20180355038A1 (en) * 2015-09-23 2018-12-13 Regeneron Pharmaceuticals, Inc. Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
KR20180100305A (ko) 2015-10-23 2018-09-10 메뤼스 엔.페. 암 성장을 억제하는 결합 분자
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene

Also Published As

Publication number Publication date
US20240174756A1 (en) 2024-05-30
SG11202001050PA (en) 2020-03-30
TWI874301B (zh) 2025-03-01
MA49846B1 (fr) 2025-05-30
PH12020550055A1 (en) 2020-10-19
US20200247892A1 (en) 2020-08-06
DK3665198T3 (da) 2025-04-28
IL272461A (en) 2020-03-31
AU2021202874A1 (en) 2021-06-03
CN119119283A (zh) 2024-12-13
HRP20250474T1 (hr) 2025-06-06
EA202090215A1 (ru) 2020-07-01
CN111094351A (zh) 2020-05-01
ES3025738T9 (en) 2025-07-10
EP3665198B9 (en) 2025-05-21
KR20200042485A (ko) 2020-04-23
PT3665198T (pt) 2025-05-02
FI3665198T3 (fi) 2025-04-25
JP2024029049A (ja) 2024-03-05
US11773170B2 (en) 2023-10-03
AU2018312816B2 (en) 2021-05-27
CN111094351B (zh) 2024-07-12
TW201910354A (zh) 2019-03-16
ES3025738T3 (en) 2025-06-09
AU2018312816A1 (en) 2020-02-27
WO2019031965A1 (en) 2019-02-14
EP4553088A2 (en) 2025-05-14
RS66708B1 (sr) 2025-05-30
CN118562014A (zh) 2024-08-30
EP3665198B1 (en) 2025-01-22
LT3665198T (lt) 2025-05-26
MA49846A (fr) 2020-06-17
JP2020530028A (ja) 2020-10-15
BR112020002695A2 (pt) 2020-08-25
AU2021202874B2 (en) 2024-10-10
PL3665198T3 (pl) 2025-06-09
FI3665198T9 (fi) 2025-07-02
EP3665198A1 (en) 2020-06-17
SI3665198T1 (sl) 2025-06-30
CA3072404A1 (en) 2019-02-14
CN118580366A (zh) 2024-09-03
MA71419A (fr) 2025-04-30

Similar Documents

Publication Publication Date Title
PH12020550055A1 (en) Antibodies that bind egfr and cmet
PH12021552798A1 (en) Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
EP3889174A4 (en) BISPECIFIC HOMODIMER-TYPE ANTIBODY AGAINST HER2 AND CD3 AND USE THEREOF
SG10201801219VA (en) Anti-HER2 Antibodies
EA201990171A1 (ru) Биспецифичное антитело против egfr и против cd3 и его применения
AU2018275359A1 (en) Antibodies specific for FLT3 and their uses
MY199406A (en) Bispecific antibodies specifically binding to pd1 and lag3
MX2020004410A (es) Anticuerpos biespecificos con funciones efectoras reducidas.
NZ732628A (en) Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof
HK1202431A1 (en) Humanized pan-her antibody compositions
PH12016502064A1 (en) Human antibodies to middle east respiratory syndrome-coronavirus spike protein
MY179866A (en) Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof
EP3991748A3 (en) Anti-sortilin antibodies and methods of use thereof
SG10201908460YA (en) Anti-egfr antibodies and antibody drug conjugates
NZ720353A (en) Fabs-in-tandem immunoglobulin and uses thereof
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
PH12012502022B1 (en) Anti-erbb3 antibodies
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
MX2016003256A (es) Anticuerpos modificados del receptor de factor de crecimiento anti-epidermico y metodos de uso de los mismos.
WO2015050959A8 (en) Anti-kit antibodies and methods of use thereof
EP3831852A4 (en) ANTIBODIES BINDING TO HUMAN HER2, METHOD FOR PREPARATION AND USE
MX2019011585A (es) Anticuerpos miltiespecificos estables.
BR112013003257A2 (pt) anticorpos egfr humanizados.
PH12019501605A1 (en) Glucagon receptor binding proteins and methods of use thereof